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ABSTRACT
Objectives: We measured the health-related quality of life
(HRQL) of diabetes mellitus patients using the Japanese ver-
sion of EQ-5D, and examined the relationship between clin-
ical condition and health status.
Methods: A study was conducted on 220 patients with type
2 diabetes mellitus at a hospital in Saitama Prefecture on the
day of their visit from November 17 to December 24, 1998.
Patients evaluated their health status using ﬁve dimensions
(5D) and a visual analog scale (VAS). The EQ-5D score was
calculated based on the 5D responses using the Japanese ver-
sion of the value set.
Results: There were no responses of “extreme problem.”
The frequency of “some problem” was signiﬁcantly higher in
patients with complications than in those without for mobil-
ity (27.4% and 14.4%) and anxiety/depression (25.7% and
13.5%). The mean EQ-5D score was 0.846 (95% conﬁdence
interval [CI] 0.817–0.874) in patients with complications
versus 0.884 (95% CI 0.855–0.914) in those without com-
plications. There was no statistically signiﬁcant difference
between VAS scores according to the presence or absence of
diabetic complications, but a signiﬁcant difference in VAS
scores was seen according to the presence or absence of
retinopathy.
Conclusion: These ﬁndings suggest the value of measuring
health status in diabetes mellitus patients, because it is able to
comprehensively evaluate the patient’s health condition, and
add another dimension to the subjective symptoms and lab-
oratory data.
Keywords: diabetes mellitus, diabetic complication, EQ-5D,
quality of life.
Introduction
Diabetes is not a curable disease; the treatment strat-
egy is to enable patients to lead lives similar to those of
healthy persons, while preventing complications
through appropriate treatment and personal manage-
ment. To achieve this objective, it is important to
reduce psychological, physical, and lifestyle burdens
and restrictions due to diabetes as much as possible.
Evaluation of health-related quality of life (HRQL) is
important for evaluating the burden on patients and in
selecting treatment methods. HRQL measurement
provides a comprehensive evaluation of the patient’s
health status which would provide additional informa-
tion to laboratory data and subjective symptoms.
We measured HRQL in patients with type 2 diabe-
tes using EQ-5D, one of the preference-based measures
among HRQL instruments that enable calculation of
the utility value. We investigated the relationship
between the clinical condition and health status, and
predicted that HRQL would worsen as a result of poor
blood glucose control, the existence of diabetic com-
plications, and insulin treatment.
Epidemiology and Economic Impact of Diabetes Mellitus 
in Japan
The Ministry of Health, Labor and Welfare conducted
surveys on diabetes targeted at residents aged 20 years
or more, randomly selected in locations throughout
the country in the form of national nutrition surveys in
1997 and 2002. These surveys examined fasting glu-
cose level, HbAlc, and physical condition related to
diabetes, and provided estimates of the prevalence of
diabetes and diabetic complications throughout Japan.
The 2002 survey showed “persons strongly suspected
of having diabetes (including persons having HbAlc
≥6.1% and persons currently being treated)”
accounted for 9.0% of the total, while “persons for
which the possibility of diabetes was unable to be
ruled out (5.6% ≤ HbAlc < 6.1%)” accounted for
10.6% of the total. Based on these ﬁgures, there are
approximately 7.4 million persons throughout Japan
who are strongly suspected of having diabetes, and this
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ﬁgure increases to roughly 16.2 million when com-
bined with those persons in whom the possibility of
diabetes cannot be ruled out. In addition, 15.6% of
those persons strongly suspected of having diabetes
had neurological disorders, 13.1% had retinopathy,
and 15.2% had nephropathy. These ﬁgures are higher
compared with the 1997 survey [1]. These high prev-
alence rates are reﬂected in high resource utilization
and expenditure. Roughly 2.12 million people
attended a medical institution for diabetes as of 1999,
and the resulting medical expenditure was estimated to
be ¥1.174 trillion as of 2001. Starting in 1979, when
statistics on the medical expenditure of individual dis-
eases were ﬁrst compiled, the rate of increase in med-
ical expenditure for diabetes has been huge and greater
than those for cardiovascular disease and malignancies
[2,3]. Moreover, the average medical expenditure for
patients with diabetic complications was signiﬁcantly
higher compared with that for patients without com-
plications [4].
HRQL Measurement for Diabetes Mellitus
Instruments for measuring HRQL are classiﬁed into
generic types and disease-speciﬁc types. There are sev-
eral disease-speciﬁc types of instruments for diabetes,
such as the Diabetes Treatment Satisfaction Question-
naire [5,6] and the Problem Area in Diabetes Scale [7,
8], which have been translated into Japanese. Never-
theless, these two questionnaires were not commonly
used at the time of the survey and had not been fully
validated. Although subtle changes in HRQL can be
measured using disease-speciﬁc types of HRQL instru-
ments, they cannot be compared among diseases.
Among generic instruments, EQ-5D, WHOQOL,
Health Utility Index, Quality of Well-Being, and SF-36
have been used internationally. We selected EQ-5D
because, among these instruments, it has the advantage
of being able to calculate a single comprehensive scalar
unit of values that can be compared among diseases
and used for economic evaluation. EQ-5D is a prefer-
ence-based HRQL questionnaire that was developed in
Europe [9]. In 1990, it was released into the public
domain, and in 1991, revised into the present form of
ﬁve dimensions (5D): mobility, self-care, usual activi-
ties, pain/discomfort, and anxiety/depression. The EQ-
5D Japanese version was prepared according to the
translated manual of the EuroQOL Group and con-
ﬁrmed by forward and backward translation. Its valid-
ity was conﬁrmed by statistical certiﬁcation, which
was performed using the general Japanese population.
From these results, it was approved as the formal
Japanese edition on November 12, 1997 [10].
Patients select three statements that best describe
their health status for each of the ﬁve dimensions of
the EQ-5D: “no problem,” “some problem,” and
“extreme problem.” Responses to the ﬁve dimensions
are collectively expressed in the standard way as an
EQ-5D score using the value set, which ranges from 1
for  full  health  (no  problem  in  any  dimension)  to
−0.111 for severe problems in all ﬁve dimensions. The
Japanese version of the value set was developed by the
Japanese EuroQol Translation Team based on the sur-
vey of the time trade-off evaluations for the general
population in Japan [11]. EQ-5D also contains a visual
analog scale (VAS), which patients indicate on a 100-
point scale. The best state carries a score of 100 and
the worst state a score of 0.
Questions have been raised about the sensitivity of
the EQ-5D for evaluating the level of advancement of
diabetes and the therapeutic efﬁcacy. Nevertheless, the
preference-based measurements which calculate health
status in different diseases are generally used for
resource allocation and its justiﬁcation in the process
of determining health-care policy by using the health
status for cost-utility analysis. Although these indica-
tors are therefore based on the assumption that these
values are valid to health conditions of any disease, it
remains to be examined what the sensitivity is for each
disease. In fact, HRQL is measured using the EQ-5D
for a variety of diseases, including diabetes.
The study has examined whether the EQ-5D can be
used for the measurement of HRQL in diabetes. In
particular, its relationship to therapeutic methods and
the presence or absence of complications and their
severity, which inﬂuence HRQL, have been examined.
Participants and Methods
Data Collection
We used two types of questionnaires, one to be ﬁlled in
by physicians, and the other by patients. The former
consisted of patient demographics, history of diabetes,
laboratory data (HbA1c and fasting blood glucose),
the type and severity of complications (microvascular
complications such as neuropathy, retinopathy, neph-
ropathy, and lower extremity lesions), and treatment
given. Diabetes mellitus was diagnosed and classiﬁed
based on the World Health Organization classiﬁcation
[12]. The details of treatment for diabetes, laboratory
data, presence of complications, and treatment of com-
plications at the time of the survey were extracted from
the medical records. The laboratory data (HbA1c and
fasting plasma glucose) used were those obtained at
the last attendance before the survey, and the level of
blood glucose control based on HbA1c was classiﬁed
based on the criteria by the Japan Diabetes Society as
follows: “excellent,” less than 5.8%; “good,” 5.8% to
6.4%; “fair,” 6.5% to 7.9%; and “poor,” more than
8% [13]. Neuropathy was classiﬁed as present if there
were symptoms due to nerve damage or by the absence
of an Achilles tendon reﬂex if there were no symptoms.
The presence or absence of neuropathy was surveyed
for each of 12 subjective symptoms associated with
neuropathy, including dizziness on standing, sweating,
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constipation/diarrhea, dysuria, erectile disorder,
numbness of limbs, pain in limbs, coldness of limbs,
burning sensation of limbs, discomfort in soles, and
cramps calf, and the severity of neuropathy was
expressed by the number of the symptoms present.
Retinopathy was classiﬁed as present if the Fukuda
classiﬁcation [14] was at least A1. Nephropathy was
classiﬁed as present if early stage urinary albumin/
create ratio was >20 mg/g. Lower extremity lesions
were classiﬁed as present if there was arteriosclerosis
obliterans or diabetic ulcers/gangrene. The survey
included outpatients and excluded inpatients for the
treatment of complications and outpatients under-
going dialysis, in consideration of other factors besides
diabetes that may inﬂuence HRQL. In addition,
patients who had lost their eyesight were excluded as
they would not be able to give written answers to the
questionnaire.
For the patient questionnaire, we prepared a form
that included occupation, alcohol and smoking habit,
the time when ﬁrst diagnosed, subjective symptoms
related to neuropathy, and health status. To determine
the health status, the EQ-5D questionnaire was used,
and the EQ-5D score was calculated using the Japa-
nese version of the value set.
The participants were 220 patients with type 2 dia-
betes mellitus who were being treated at a hospital in
Saitama Prefecture from November 17 to December
24, 1998. Because diabetic patients attend hospital
once a month in Japan, a 1-month survey would cover
almost all patients attending the outpatient depart-
ment. A questionnaire was completed by patients
before treatment to eliminate the effects of treatment
on the day. Although the patients were given the
option of not responding, all responded after explana-
tion of the purpose of the study.
Statistical Analysis
Analysis of variance was performed to compare EQ-
5D score and VAS scores between groups after adjust-
ing for age and sex. Chi-square test was performed for
the ﬁve dimensions of health status. The measured
data were expressed as mean ± standard deviation and
considered statistically signiﬁcant at P < 0.05. As there
were signiﬁcant differences in EQ-5D and VAS scores
according to sex and age, the mean values were
adjusted by these parameters using analysis of covari-
ance (ANCOVA). MS-EXCEL and SPSS were used for
the calculations and analyses.
Results
Patient Demographics
Table 1 shows the demographics of the patients stud-
ied. There were 110 male (50.0%) and 110 female par-
ticipants (50.0%); 78 patients (35.5%) were treated by
diet and exercise therapy, 100 (45.5%) received oral
hypoglycemic agents (OHA), and 42 (19.1%) received
insulin therapy (including those given both insulin and
OHA). HbA1c control was classiﬁed as “fair” in 42
patients (19.3%), “good” in 55 (25.2%), “poor” in 73
(33.5%), and “improper” in 48 (22.0%). Concerning
diabetic complications, there were 94 cases (42.7%) of
neuropathy, 55 (25.0%) of retinopathy, 12 (5.5%) of
nephropathy, and 19 (8.6%) of lower extremity
lesions. At least one of these four complications was
present in 114 patients (51.8%). Patients suffering
from severe diabetic complications (i.e., proliferative
retinopathy, albumin/creatine ratio greater than
220 mg/g, or serum creatinine greater than 1.4 mg/dL)
were excluded, so that the participants were limited to
those with mild to moderate diabetes mellitus. The
mean duration of diabetes (period from the time of
ﬁrst diagnosis to the time of the survey) was
8.5 ± 8.1 years, mean age was 63.3 ± 10.3 years old,
and mean HbA1c was 6.9 ± 1.4%.
Health Status (Table 2)
For the ﬁve dimensions of EQ-5D, the number of
patients responding as having “some problem” was
46 (21.2%) for mobility, 6 (2.8%) for self-care, 37
(17.3%) for usual activities, 76 (35.7%) for pain/
discomfort, and 42 (19.7%) for anxiety/depression.
There were no responses of “extreme problem” for
any of the dimensions. The frequency for “some prob-
lem” was high for pain/discomfort and low for usual
activities.
As there were no responses of “extreme problem,”
chi-square test was performed for differences in the
response of “no problem” and “some problem.”
Examination of health status according to sex and age
revealed that for mobility and anxiety/depression, the
Table 1 Demographics of patients
Number of patients 220
Male 110 (50.0%)
Age (year)
Mean ± SD 63.3 ± 10.3
Range 29–89
Duration of diabetes (year)
Mean ± SD 8.5 ± 8.1
Range 0–42
HbA1c level
Mean ± SD 6.9 ± 1.4%
Range 4.8–11.7%
Treatment
Diet and exercise 78 (35.5%)






Lower extremity lesions 19 (8.6%)
Any diabetic complication 114 (51.8%)
Note: Any diabetic complications: cases with at least one out of neuropathy, retin-
opathy, nephropathy, and foot lesions.
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frequency of “some problem” was higher in females. It
was statistically signiﬁcant for anxiety/depression (P <
0.01). In the elderly, the frequency of “some problem”
responses in the 70 years and older group was signif-
icantly higher than that in the other age groups for
mobility and usual activities (P < 0.01). For the rela-
tionship between the presence of diabetic complica-
tions and health status, the frequency of “some
problem” responses was signiﬁcantly higher for mobil-
ity in patients with neuropathy. For both the duration
of diabetes and lower extremity lesions, there were no
statistically signiﬁcant differences in the frequency of
“some problem.” Comparison between patients with
at least one complication of neuropathy, retinopathy,
nephropathy, and lower extremity lesions and those
with no complications showed that the frequency of
“some problem” was signiﬁcantly higher for mobility
and anxiety/depression in those with complications.
Nevertheless, the presence of complications did not
show a statistically signiﬁcant relationship for the
other dimensions. The frequency of “some problem”
for mobility was 27.4% in those with complications,
compared with 14.4% in those without complications
(P < 0.05). The frequency of “some problem” for anx-
iety/depression was 25.7% in those with complica-
tions compared with 13.5% in those without
complications (P < 0.05).
EQ-5D and VAS Scores (Table 3)
The mean EQ-5D score calculated from the 5D
responses was 0.862 and the mean VAS score was
74.3. The EQ-5D score was slightly lower in females
(0.84; 95% conﬁdence interval [CI] 0.81–0.87) than in
males (0.89; 95% CI 0.86–0.92) (P < 0.05). There
Table 2 Diabetic complications and EQ-5D
Mobility Self-care Usual activities Pain/discomfort Anxiety/depression
% of any 
problems P-value
% of any 
problems P-value
% of any 
problems P-value
% of any 
problems P-value
% of any 
problems P-value
Sex
Male 13.9 0.012† 1.9 0.445 13.9 0.208 33.3 0.478 12.1 0.006*
Female 28.4 3.7 20.8 38.1 27.4
Age group (year)
≤49 11.1 0.000* 0.0 0.151 11.1 0.007* 38.9 0.492 16.7 0.499
50–59 7.9 0.0 7.9 32.8 23.4
60–69 15.5 2.9 15.5 30.9 14.3
≥70 30.6 6.3 30.6 42.9 23.0
Treatment
Diet and exercise 19.7 0.923 2.6 0.968 20.3 0.557 33.3 0.550 17.6 0.494
OHA 22.2 3.1 14.3 34.4 18.6
Insulin 21.4 2.4 19.0 42.9 26.2
HbA1c level
Excellent: ≤5.7% 14.6 0.397 2.4 0.800 22.0 0.741 36.6 0.416 15.0 0.524
Good: 5.8%−6.4% 21.8 3.6 16.4 27.3 16.4
Fair: 6.5%−7.9% 19.7 1.4 14.3 38.2 21.4
Poor: ≥8.0% 29.2 4.3 19.6 42.6 26.1
Neuropathy
Presence 28.0 0.044† 3.3 0.700 18.7 0.716 34.4 0.774 24.7 0.152
Absence 16.1 2.4 16.3 36.6 16.1
Retinopathy
Presence 21.8 1.000 0.0 0.341 18.2 0.828 32.1 0.62 25.5 0.239
Absence 21.0 3.7 17.0 36.9 17.7
Nephropathy
Presence 41.7 0.136 9.1 0.273 33.3 0.133 45.5 0.527 25.0 0.708
Absence 20.0 2.5 16.3 35.1 15.2
Lower extremity lesions
Presence 33.3 0.226 5.6 0.412 16.7 1.000 38.9 0.800 11.1 0.536
Absence 20.1 2.5 17.3 35.4 20.5
Any diabetic complications
Presence 27.4 0.021† 4.5 0.214 18.9 0.589 38.2 0.476 25.7 0.026†
Absence 14.4 1.0 15.5 33.0 13.5
Number of subjective symptoms
0 12.3 0.000* 1.4 0.014† 12.3 0.000* 21.1 0.000* 11.1 0.000*
1 15.4 3.1 7.9 29.7 7.9
2 20.9 0.0 16.3 41.9 25.6
3 42.9 0.0 42.9 57.1 38.5
≥4 54.5 14.3 47.6 76.2 59.1
Total
Number of respondents 217 215 214 213 213
% of any problems 21.2 2.8 17.3 35.7 19.7
*P < 0.01.
†P < 0.05.
Notes: P-value: chi-square test; No marks: not signiﬁcant.
OHA, oral hypoglycemic agents.
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were no signiﬁcant differences in EQ-5D scores among
age groups less than 70 years, but the EQ-5D scores in
patients 70 years and older was signiﬁcantly lower
than that in the 50 years and younger group and 50 to
59 years group. Because of these differences, adjust-
ments were made by age and sex before statistical
analyses.
There was no statistically signiﬁcant relationship
between treatments and EQ-5D score: the EQ-5D
score was 0.87 (95% CI 0.83–0.90) in patients receiv-
ing diet and exercise therapy, 0.88 (95% CI 0.85–0.91)
in those receiving OHA, and 0.83 (95% CI 0.79–0.88)
in those receiving insulin. There were no statistically
signiﬁcant relationship between HbA1c level and EQ-
5D score, but there was a signiﬁcant relationship
between HbA1c level and VAS score (P < 0.01). There
was no signiﬁcant relationship between EQ-5D score
and the presence of complications of neuropathy,
retinopathy, nephropathy, and lower extremity lesions.
Nevertheless, the mean EQ-5D score was lower in
patients with at least one complication (0.85; 95% CI
0.82–0.87) than in those without complications (0.88;
95% CI 0.86–0.91) (P = 0.066, ns).
The health status expressed by VAS score was sim-
ilar to that expressed by EQ-5D scores, and there was
a statistical relationship between EQ-5D score and
VAS score (Spearman correlation test, P = 0.331;
P < 0.01). Nevertheless, unlike the EQ-5D score, there
were no statistically signiﬁcant differences between
males and females and among age groups for the VAS
score. Differences in VAS scores were also observed
according to the presence or absence of retinopathy
and nephropathy, which were not observed for the 5D
and EQ-5D score. There were no differences in VAS
scores according to the presence or absence of diabetic
complications. There was no relationship between the
number of diabetic complications and the EQ-5D or
VAS score.
Table 3 Diabetic complications and EQ-5D score, VAS score
EQ-5D score VAS score 
Mean (95% CI) P-value Mean (95% CI) P-value
Total 0.86 (0.83–0.88) 74.3 (72.1–76.6)
Sex
Male 0.89 (0.86–0.92) 0.021* 74.2 (71.1–77.2) 0.819
Female 0.84 (0.81–0.87) 74.7 (71.4–77.9)
Age group (year)
≤49 0.87 (0.80–0.94) 0.033* 80.5 (73.1–87.9) 0.239
50–59 0.89 (0.86–0.93) 75.8 (72.3–79.4)
60–69 0.88 (0.85–0.92) 73.7 (69.4–78.0)
≥70 0.82 (0.77–0.86) 72.2 (67.9–76.4)
Treatment
Diet and exercise 0.87 (0.83–0.90) 0.298 75.3 (71.5–79.1) 0.809
OHA 0.88 (0.85–0.91) 74.3 (71.0–77.0)
Insulin 0.83 (0.79–0.88) 73.2 (68.2–78.2)
HbA1c level
Excellent: ≤5.7% 0.87 (0.82–0.92) 0.739 76.8 (72.5–82.9) 0.002†
Good: 5.8%−6.4% 0.88 (0.84–0.92) 77.9 (73.7–82.1)
Fair: 6.5%−7.9% 0.86 (0.92–0.89) 76.0 (72.4–79.6)
Poor: ≥8.0% 0.85 (0.80–0.90) 66.7 (62.2–71.3)
Neuropathy
Presence 0.85 (0.82–0.89) 0.323 73.1 (69.8–76.4) 0.294
Absence 0.87 (0.85–0.90) 75.4 (72.5–78.3)
Retinopathy
Presence 0.86 (0.81–0.90) 0.939 70.3 (66.0–74.5) 0.034*
Absence 0.87 (0.84–0.89) 75.8 (73.3–78.4)
Nephropathy
Presence 0.81 (0.72–0.90) 0.193 59.6 (50.2–69.0) 0.002†
Absence 0.87 (0.85–0.89) 75.2 (73.0–77.4)
Lower extremity lesions
Presence 0.84 (0.77–0.91) 0.543 69.2 (61.8–76.6) 0.147
Absence 0.87 (0.85–0.89) 74.9 (72.6–77.2)
Any diabetic complications
Presence 0.85 (0.82–0.87) 0.066 72.7 (69.7–75.7) 0.111
Absence 0.88 (0.86–0.91) 76.3 (73.1–79.5)
Number of subjective symptoms
0 0.91 (0.87–0.94) 0.026† 76.03 (72.3–79.6) 0.000†
1 0.90 (0.67–0.94) 77.63 (74.0–81.6)
2 0.85 (0.80–0.89) 77.07 871.9–81.3)
3 0.76 (0.68–0.84) 68.00 (59.9–75.5)
≥4 0.71 (0.64–0.77) 58.67 (52.9–66.3)
*P < 0.05.
†P < 0.01.
Notes: EQ-5D and VAS scores: mean values adjusted by sex and age; P-value: ANCOVA; No marks: not signiﬁcant.
CI, conﬁdence interval; OHA, oral hypoglycemic agents; VAS, visual analog scale.
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Discussion
We measured the health status by EQ-5D and calcu-
lated the EQ-5D score using the Japanese value set in
patients with type 2 diabetes mellitus, to investigate
the relationship between EQ-5D and VAS scores and
the clinical condition.
In this research, we predicted that HRQL decreases
because of the existence of complications from diabe-
tes and insulin treatment, and included demographic
parameters of the patients, the presence of complica-
tions, the presence of treatment for retinopathy, and
current treatment method. Nevertheless, a signiﬁcant
difference in EQ-5D was found only for mobility in
patients with neuropathy, and there were no signiﬁcant
differences in any of the other EQ-5D scores calculated
by the value set.
In the case of diabetes mellitus, HRQL has been
reported to worsen considerably as complications
become increasingly serious and with the onset of dial-
ysis [15]. In addition, visual impairment is also con-
sidered to contribute to a lower HRQL. The type 2
diabetes patients targeted in this research had compli-
cations, but these were comparatively mild, and for
this reason, there was no large decrease in HRQL.
Thus, HRQL is thought to not decrease signiﬁcantly in
patients with mild complications.
Subjective symptoms and EQ-5D health status were
strongly related, which was reﬂected in the HRQL.
Most importantly, a signiﬁcant relationship between
the number of subjective symptoms and EQ-5D score
was observed. This was particularly signiﬁcant for
patients who had four or more subjective symptoms, in
whom the EQ-5D score decreased to 0.71. This score
was similar to that for rheumatoid arthritis patients in
functional class 1, which has been reported as 0.74
[16].
Whereas the EQ-5D score measures HRQL indi-
rectly from the ﬁve domains, the VAS measures it
directly by the patient’s subjective feeling. Therefore,
the VAS more clearly shows the severity of the disease
which the patient himself/herself experiences.
The EQ-5D has been used in the UK Prospective
Diabetes Study (UKPDS) to determine the effects of
therapy, complications, and hypoglycemic episodes on
HRQL in patients with type 2 diabetes [17]. Two
cross-sectional and longitudinal studies from the
UKPDS were conducted. In the cross-sectional study,
there was no statistically signiﬁcant relationship
between insulin and OHA treatment and the EQ-5D
score. Concerning the relationship between diabetic
complications and EQ-5D, patients with microvascu-
lar complications had lower EQ-5D scores and a
higher percentage of problems in the 5D, but these
were not statistically signiﬁcant. The results of the rela-
tionships between EQ-5D and treatment, and EQ-5D
and complications were similar.
In conclusion, we demonstrated the relationship
between patients’ subjective symptoms and EQ-5D,
and that the EQ-5D score was affected by the number
of symptoms. The EQ-5D score may also be able to
detect subtle aspects that cannot be gathered by asking
patients about their symptoms. Nevertheless, the EQ-
5D, which is less sensitive than disease-speciﬁc scales,
should be used in combination with the disease-speciﬁc
scale for clinical evaluations. ED-5D scores alone
appear to be more suitable for cost-utility analyses.
Conclusion
This study focused on patients with mild to moderate
type 2 diabetes mellitus, measuring their health status
and EQ-5D score. The mean EQ-5D score of diabetic
patients with microvascular complications was 0.846
(95% CI 0.817–0.874), compared with 0.884 in those
without (95% CI 0.855–0.914). The study showed
that there was no detectable difference in EQ-5D
among drug therapies. Although no relationship
between the presence of complications and EQ-5D was
detected, EQ-5D clearly decreased if subjective symp-
toms were present and reﬂected the characteristic of
each of the 5D. These ﬁndings suggest the value of
measuring health status in diabetes mellitus patients by
EQ-5D, because it would allow comprehensive evalu-
ation of the patient’s health condition, and add
another dimension to the subjective symptoms and
laboratory data. Nevertheless, the EQ-5D, which is
less sensitive than disease-speciﬁc scales, should be
used in combination with the disease-speciﬁc scale for
clinical evaluations.
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